{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T02:08:14Z","timestamp":1794708494992,"version":"4.9.1"},"reference-count":240,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T00:00:00Z","timestamp":1605484800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017331","name":"Ministry of Innovation, Science, Research and Technology of the State of North Rhine-Westphalia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["CRC 1116\/2"],"award-info":[{"award-number":["CRC 1116\/2"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003107","name":"Bundesministerium f\u00fcr Gesundheit","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003107","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Metabolism"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.molmet.2020.101122","type":"journal-article","created":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T23:00:56Z","timestamp":1605826856000},"page":"101122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":313,"special_numbering":"C","title":["Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans"],"prefix":"10.1016","volume":"50","author":[{"given":"Kalliopi","family":"Pafili","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8200-6382","authenticated-orcid":false,"given":"Michael","family":"Roden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmet.2020.101122_bib1","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1053\/j.gastro.2020.01.052","article-title":"Nonalcoholic fatty liver disease 2020: the State of the disease","volume":"158","author":"Cotter","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmet.2020.101122_bib2","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/ncpendmet0190","article-title":"Mechanisms of disease: hepatic steatosis in type 2 diabetes-pathogenesis and clinical relevance","volume":"2","author":"Roden","year":"2006","journal-title":"Nature Clinical Practice Endocrinology & Metabolism"},{"key":"10.1016\/j.molmet.2020.101122_bib3","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/14656566.2017.1413346","article-title":"Ipragliflozin and sodium glucose transporter 2 inhibitors to reduce liver fat: will the prize we sought be won?","volume":"19","author":"Pafili","year":"2018","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1016\/j.molmet.2020.101122_bib4","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S2213-8587(19)30187-1","article-title":"Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study","volume":"7","author":"Zaharia","year":"2019","journal-title":"The Lancet Diabetes & Endocrinology"},{"key":"10.1016\/j.molmet.2020.101122_bib5","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrgastro.2013.41","article-title":"Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis","volume":"10","author":"Anstee","year":"2013","journal-title":"Nature Reviews Gastroenterology & Hepatology"},{"key":"10.1016\/j.molmet.2020.101122_bib6","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrendo.2017.173","article-title":"Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus","volume":"14","author":"Targher","year":"2018","journal-title":"Nature Reviews Endocrinology"},{"key":"10.1016\/j.molmet.2020.101122_bib7","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0016-5085(98)70599-2","article-title":"Steatohepatitis: a tale of two \"hits\"?","volume":"114","author":"Day","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmet.2020.101122_bib8","doi-asserted-by":"crossref","first-page":"21833","DOI":"10.3390\/ijms141121833","article-title":"Rodent models of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"14","author":"Imajo","year":"2013","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.molmet.2020.101122_bib9","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/hep.24001","article-title":"Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis","volume":"52","author":"Tilg","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.molmet.2020.101122_bib10","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.molmet.2020.101122_bib11","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2337\/dc19-0641","article-title":"Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial","volume":"43","author":"Kahl","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.molmet.2020.101122_bib12","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.molmet.2020.101122_bib13","article-title":"Metabolic liver disease in diabetes - from mechanisms to clinical trials","volume":"154299","author":"Dewidar","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.molmet.2020.101122_bib14","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12902-020-00582-9","article-title":"Impact of obesity and metabolic health status in the development of non-alcoholic fatty liver disease (NAFLD): a United Kingdom population-based cohort study using the health improvement network (THIN)","volume":"20","author":"Vusirikala","year":"2020","journal-title":"BMC Endocrine Disorders"},{"key":"10.1016\/j.molmet.2020.101122_bib15","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S2468-1253(20)30077-7","article-title":"Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"5","author":"Ye","year":"2020","journal-title":"The Lancet Gastroenterology & Hepatology"},{"key":"10.1016\/j.molmet.2020.101122_bib16","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S2213-8587(18)30051-2","article-title":"Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables","volume":"6","author":"Ahlqvist","year":"2018","journal-title":"The Lancet Diabetes & Endocrinology"},{"key":"10.1016\/j.molmet.2020.101122_bib17","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.2337\/dc20-0329","article-title":"Role of patatin-like phospholipase domain\u2013containing 3 gene for hepatic lipid content and insulin resistance in diabetes","volume":"43","author":"Oana","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.molmet.2020.101122_bib18","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.metabol.2016.06.009","article-title":"Non-alcoholic fatty liver disease with and without metabolic syndrome: different long-term outcomes","volume":"66","author":"Karajamaki","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.molmet.2020.101122_bib19","doi-asserted-by":"crossref","unstructured":"Shi Y, Wang Q, Sun Y, Zhao X, Kong Y, Ou X, et al. The prevalence of lean\/nonobese nonalcoholic fatty liver disease: a systematic review and meta-analysis. Journal of Clinical Gastroenterology;54:378-387.","DOI":"10.1097\/MCG.0000000000001270"},{"key":"10.1016\/j.molmet.2020.101122_bib20","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/hep4.1534","article-title":"Mortality of NAFLD according to the body composition and presence of metabolic abnormalities","volume":"4","author":"Golabi","year":"2020","journal-title":"Hepatology Communications"},{"key":"10.1016\/j.molmet.2020.101122_bib21","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1053\/j.gastro.2015.08.011","article-title":"Heritability of hepatic fibrosis and steatosis based on a prospective twin study","volume":"149","author":"Loomba","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmet.2020.101122_bib22","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1002\/hep.24283","article-title":"Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease","volume":"53","author":"Sookoian","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.molmet.2020.101122_bib23","doi-asserted-by":"crossref","first-page":"389","DOI":"10.7555\/JBR.32.20180045","article-title":"Non-alcoholic fatty liver disease: a narrative review of genetics","volume":"32","author":"Danford","year":"2018","journal-title":"Journal of Biomedical Research"},{"key":"10.1016\/j.molmet.2020.101122_bib24","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1007\/s00125-014-3310-0","article-title":"PNPLA3 variant I148M is associated with altered hepatic lipid composition in humans","volume":"57","author":"Peter","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.molmet.2020.101122_bib25","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/hep.27490","article-title":"Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease","volume":"61","author":"Dongiovanni","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.molmet.2020.101122_bib26","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/hep.28370","article-title":"The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage","volume":"63","author":"Donati","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.molmet.2020.101122_bib27","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nature Genetics"},{"key":"10.1016\/j.molmet.2020.101122_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140427","article-title":"The impact of PNPLA3 rs738409 genetic polymorphism and weight gain >\/=10 kg after age 20 on non-alcoholic fatty liver disease in non-obese Japanese individuals","volume":"10","author":"Nishioji","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.molmet.2020.101122_bib29","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s12328-018-0841-9","article-title":"The genetic backgrounds in nonalcoholic fatty liver disease","volume":"11","author":"Seko","year":"2018","journal-title":"Clinical Journal of Gastroenterology"},{"key":"10.1016\/j.molmet.2020.101122_bib30","doi-asserted-by":"crossref","first-page":"15756","DOI":"10.1038\/s41598-017-15943-z","article-title":"PNPLA3 variant and portal\/periportal histological pattern in patients with biopsy-proven non-alcoholic fatty liver disease: a possible role for oxidative stress","volume":"7","author":"Carpino","year":"2017","journal-title":"Scientific Reports"},{"key":"10.1016\/j.molmet.2020.101122_bib31","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/hep.23759","article-title":"The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease","volume":"52","author":"Rotman","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.molmet.2020.101122_bib32","doi-asserted-by":"crossref","first-page":"E162","DOI":"10.1111\/hepr.12940","article-title":"Effect of PNPLA3 I148M polymorphism on histologically proven non-alcoholic fatty liver disease in liver transplant recipients","volume":"48","author":"Kim","year":"2018","journal-title":"Hepatology Research"},{"key":"10.1016\/j.molmet.2020.101122_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0038322","article-title":"Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese","volume":"7","author":"Kawaguchi","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.molmet.2020.101122_bib34","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jhep.2020.04.003","article-title":"Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort","volume":"73","author":"Anstee","year":"2020","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.molmet.2020.101122_bib35","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1194\/jlr.P067454","article-title":"Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study","volume":"58","author":"Krawczyk","year":"2017","journal-title":"The Journal of Lipid Research"},{"key":"10.1016\/j.molmet.2020.101122_bib36","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1194\/jlr.P900013-JLR200","article-title":"A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity","volume":"50","author":"Sookoian","year":"2009","journal-title":"The Journal of Lipid Research"},{"key":"10.1016\/j.molmet.2020.101122_bib37","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.127902","article-title":"Human PNPLA3-I148M variant increases hepatic retention of polyunsaturated fatty acids","volume":"4","author":"Luukkonen","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.molmet.2020.101122_bib38","doi-asserted-by":"crossref","first-page":"8913","DOI":"10.1073\/pnas.1323785111","article-title":"TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content","volume":"111","author":"Mahdessian","year":"2014","journal-title":"Proceedings of the National Academy of Sciences of the U S A"},{"key":"10.1016\/j.molmet.2020.101122_bib39","doi-asserted-by":"crossref","first-page":"10659","DOI":"10.1074\/jbc.M116.719955","article-title":"Inactivation of Tm6sf2, a gene defective in fatty liver disease, impairs lipidation but not secretion of very low density lipoproteins","volume":"291","author":"Smagris","year":"2016","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.molmet.2020.101122_bib40","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.1038\/ncomms5309","article-title":"TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease","volume":"5","author":"Liu","year":"2014","journal-title":"Nature Communications"},{"key":"10.1016\/j.molmet.2020.101122_bib41","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/hep.30908","article-title":"Lean NAFLD: a distinct entity shaped by differential metabolic adaptation","volume":"71","author":"Chen","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.molmet.2020.101122_bib42","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/MOL.0000000000000155","article-title":"Glucokinase regulatory protein: complexity at the crossroads of triglyceride and glucose metabolism","volume":"26","author":"Raimondo","year":"2015","journal-title":"Current Opinion in Lipidology"},{"key":"10.1016\/j.molmet.2020.101122_bib43","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.1093\/hmg\/ddp357","article-title":"The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver","volume":"18","author":"Beer","year":"2009","journal-title":"Human Molecular Genetics"},{"key":"10.1016\/j.molmet.2020.101122_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087523","article-title":"Glucokinase regulatory protein gene polymorphism affects liver fibrosis in non-alcoholic fatty liver disease","volume":"9","author":"Petta","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.molmet.2020.101122_bib45","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1007\/s00535-013-0850-x","article-title":"Association of glucokinase regulatory gene polymorphisms with risk and severity of non-alcoholic fatty liver disease: an interaction study with adiponutrin gene","volume":"49","author":"Tan","year":"2014","journal-title":"Journal of Gastroenterology"},{"key":"10.1016\/j.molmet.2020.101122_bib46","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/hep.24806","article-title":"Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents","volume":"55","author":"Santoro","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.molmet.2020.101122_bib47","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1053\/j.gastro.2016.01.032","article-title":"The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent","volume":"150","author":"Mancina","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmet.2020.101122_bib48","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.jhep.2016.07.045","article-title":"The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans","volume":"65","author":"Luukkonen","year":"2016","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.molmet.2020.101122_bib49","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1136\/gut.2009.190801","article-title":"Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease","volume":"59","author":"Dongiovanni","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.molmet.2020.101122_bib50","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jhep.2011.05.029","article-title":"The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies","volume":"56","author":"Al-Serri","year":"2012","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.molmet.2020.101122_bib51","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.jhep.2015.10.016","article-title":"MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease","volume":"64","author":"Petta","year":"2016","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.molmet.2020.101122_bib52","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1056\/NEJMoa0907295","article-title":"Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease","volume":"362","author":"Petersen","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.molmet.2020.101122_bib53","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1093\/hmg\/ddw400","article-title":"MERTK rs4374383 variant predicts incident nonalcoholic fatty liver disease and diabetes: role of mononuclear cell activation and adipokine response to dietary fat","volume":"26","author":"Musso","year":"2017","journal-title":"Human Molecular Genetics"},{"key":"10.1016\/j.molmet.2020.101122_bib54","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1111\/liv.12707","article-title":"The UCP2 -866 G>A promoter region polymorphism is associated with nonalcoholic steatohepatitis","volume":"35","author":"Fares","year":"2015","journal-title":"Liver International"},{"key":"10.1016\/j.molmet.2020.101122_bib55","article-title":"Loss of hepatic Mboat7 leads to liver fibrosis","author":"Thangapandi","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.molmet.2020.101122_bib56","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.132158","article-title":"Hydroxysteroid 17-beta dehydrogenase 13 variant increases phospholipids and protects against fibrosis in nonalcoholic fatty liver disease","volume":"5","author":"Luukkonen","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.molmet.2020.101122_bib57","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa1712191","article-title":"A protein-truncating HSD17B13 variant and protection from chronic liver disease","volume":"378","author":"Abul-Husn","year":"2018","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.molmet.2020.101122_bib58","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/hep.30350","article-title":"17-Beta hydroxysteroid dehydrogenase 13 is a hepatic retinol dehydrogenase associated with histological features of nonalcoholic fatty liver disease","volume":"69","author":"Ma","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.molmet.2020.101122_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1001324","article-title":"Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits","volume":"7","author":"Speliotes","year":"2011","journal-title":"PLoS Genetics"},{"key":"10.1016\/j.molmet.2020.101122_bib60","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1210\/jc.2017-00056","article-title":"Fibronectin type III domain-containing protein 5 rs3480 A>G polymorphism, irisin, and liver fibrosis in patients with nonalcoholic fatty liver disease","volume":"102","author":"Petta","year":"2017","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"key":"10.1016\/j.molmet.2020.101122_bib61","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jhep.2018.10.021","article-title":"A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3'UTR","volume":"70","author":"Metwally","year":"2019","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.molmet.2020.101122_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2020.04.031","article-title":"Immunity-related GTPase induces lipophagy to prevent excess hepatic lipid accumulation","author":"Schwerbel","year":"2020","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.molmet.2020.101122_bib63","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/s42255-019-0124-x","article-title":"Hepatic Rab24 controls blood glucose homeostasis via improving mitochondrial plasticity","volume":"1","author":"Seitz","year":"2019","journal-title":"Nature Metabolism"},{"key":"10.1016\/j.molmet.2020.101122_bib64","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.2337\/db13-1622","article-title":"Overfeeding polyunsaturated and saturated fat causes distinct effects on liver and visceral fat accumulation in humans","volume":"63","author":"Rosqvist","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2020.101122_bib65","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.3945\/ajcn.111.030114","article-title":"Effects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation in abdominal obesity: a randomized controlled trial","volume":"95","author":"Bjermo","year":"2012","journal-title":"American Journal of Clinical Nutrition"},{"key":"10.1016\/j.molmet.2020.101122_bib66","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/hep.27149","article-title":"Hypercaloric diets with increased meal frequency, but not meal size, increase intrahepatic triglycerides: a randomized controlled trial","volume":"60","author":"Koopman","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.molmet.2020.101122_bib67","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1053\/j.gastro.2013.07.012","article-title":"No difference between high-fructose and high-glucose diets on liver triacylglycerol or biochemistry in healthy overweight men","volume":"145","author":"Johnston","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmet.2020.101122_bib68","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3945\/ajcn.111.022533","article-title":"Sucrose-sweetened beverages increase fat storage in the liver, muscle, and visceral fat depot: a 6-mo randomized intervention study","volume":"95","author":"Maersk","year":"2012","journal-title":"American Journal of Clinical Nutrition"},{"key":"10.1016\/j.molmet.2020.101122_bib69","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1172\/JCI89444","article-title":"Acute dietary fat intake initiates alterations in energy metabolism and insulin resistance","volume":"27","author":"Hernandez","year":"2017","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.molmet.2020.101122_bib70","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.3945\/ajcn.2008.27296","article-title":"High protein intake reduces intrahepatocellular lipid deposition in humans","volume":"90","author":"Bortolotti","year":"2009","journal-title":"American Journal of Clinical Nutrition"},{"key":"10.1016\/j.molmet.2020.101122_bib71","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.134520","article-title":"Monounsaturated fat rapidly induces hepatic gluconeogenesis and whole-body insulin resistance","volume":"5","author":"Sarabhai","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.molmet.2020.101122_bib72","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41586-019-1797-8","article-title":"The integrative biology of type 2 diabetes","volume":"576","author":"Roden","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.molmet.2020.101122_bib73","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1017\/S0007114509992819","article-title":"Effects of a short-term overfeeding with fructose or glucose in healthy young males","volume":"103","author":"Ngo Sock","year":"2010","journal-title":"British Journal of Nutrition"},{"key":"10.1016\/j.molmet.2020.101122_bib74","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.3945\/ajcn.112.035139","article-title":"Effects of supplementation with essential amino acids on intrahepatic lipid concentrations during fructose overfeeding in humans","volume":"96","author":"Theytaz","year":"2012","journal-title":"American Journal of Clinical Nutrition"},{"key":"10.1016\/j.molmet.2020.101122_bib75","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.3945\/ajcn.2008.27336","article-title":"Fructose overconsumption causes dyslipidemia and ectopic lipid deposition in healthy subjects with and without a family history of type 2 diabetes","volume":"89","author":"Le","year":"2009","journal-title":"American Journal of Clinical Nutrition"},{"key":"10.1016\/j.molmet.2020.101122_bib76","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/ejcn.2014.8","article-title":"Effect of fructose on markers of non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of controlled feeding trials","volume":"68","author":"Chiu","year":"2014","journal-title":"European Journal of Clinical Nutrition"},{"key":"10.1016\/j.molmet.2020.101122_bib77","doi-asserted-by":"crossref","first-page":"833","DOI":"10.3945\/ajcn.114.086314","article-title":"Fructose, high-fructose corn syrup, sucrose, and nonalcoholic fatty liver disease or indexes of liver health: a systematic review and meta-analysis","volume":"100","author":"Chung","year":"2014","journal-title":"American Journal of Clinical Nutrition"},{"key":"10.1016\/j.molmet.2020.101122_bib78","doi-asserted-by":"crossref","first-page":"E691","DOI":"10.1210\/jc.2010-2243","article-title":"Three weeks on a high-fat diet increases intrahepatic lipid accumulation and decreases metabolic flexibility in healthy overweight men","volume":"96","author":"van Herpen","year":"2011","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"key":"10.1016\/j.molmet.2020.101122_bib79","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1210\/jc.2004-1983","article-title":"Dietary fat content modifies liver fat in overweight nondiabetic subjects","volume":"90","author":"Westerbacka","year":"2005","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"key":"10.1016\/j.molmet.2020.101122_bib80","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.2337\/dc18-0071","article-title":"Saturated fat is more metabolically harmful for the human liver than unsaturated fat or simple sugars","volume":"41","author":"Luukkonen","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.molmet.2020.101122_bib81","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.jhep.2018.01.015","article-title":"High red and processed meat consumption is associated with non-alcoholic fatty liver disease and insulin resistance","volume":"68","author":"Zelber-Sagi","year":"2018","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.molmet.2020.101122_bib82","doi-asserted-by":"crossref","DOI":"10.3390\/nu9070667","article-title":"Fruit fiber consumption specifically improves liver health status in obese subjects under energy restriction","volume":"9","author":"Cantero","year":"2017","journal-title":"Nutrients"},{"key":"10.1016\/j.molmet.2020.101122_bib83","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.cmet.2017.04.001","article-title":"Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease","volume":"25","author":"Loomba","year":"2017","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.molmet.2020.101122_bib84","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/hep.26093","article-title":"Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH","volume":"57","author":"Zhu","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.molmet.2020.101122_bib85","first-page":"991","article-title":"Microsomal ethanol-oxidizing system (MEOS): the first 30 years (1968-1998)-a review","volume":"23","author":"Lieber","year":"1999","journal-title":"Alcoholism: Clinical and Experimental Research"},{"key":"10.1016\/j.molmet.2020.101122_bib86","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s13238-017-0436-0","article-title":"New insight into inter-organ crosstalk contributing to the pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"9","author":"Zhang","year":"2018","journal-title":"Protein Cell"},{"key":"10.1016\/j.molmet.2020.101122_bib87","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1002\/hep.22848","article-title":"Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease","volume":"49","author":"Miele","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.molmet.2020.101122_bib88","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/hep.31056","article-title":"Increased liver localization of lipopolysaccharides in human and experimental NAFLD","volume":"72","author":"Carpino","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.molmet.2020.101122_bib89","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.molmet.2016.06.003","article-title":"Non-alcoholic fatty liver and the gut microbiota","volume":"5","author":"Bashiardes","year":"2016","journal-title":"Molecular Metabolism"},{"key":"10.1016\/j.molmet.2020.101122_bib90","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1136\/gutjnl-2019-318811","article-title":"Intrahepatic bacterial metataxonomic signature in non-alcoholic fatty liver disease","volume":"69","author":"Sookoian","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.molmet.2020.101122_bib91","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1136\/gutjnl-2016-312238","article-title":"Systematic review of bariatric surgery liver biopsies clarifies the natural history of liver disease in patients with severe obesity","volume":"66","author":"Bedossa","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.molmet.2020.101122_bib92","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1016\/j.celrep.2017.05.035","article-title":"Hepatic diacylglycerol-associated protein kinase cepsilon translocation links hepatic steatosis to hepatic insulin resistance in humans","volume":"19","author":"Ter Horst","year":"2017","journal-title":"Cell Reports"},{"key":"10.1016\/j.molmet.2020.101122_bib93","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1172\/JCI77812","article-title":"The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux","volume":"126","author":"Samuel","year":"2016","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.molmet.2020.101122_bib94","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.3748\/wjg.14.2888","article-title":"Serum leptin and soluble leptin receptor in non-alcoholic fatty liver disease","volume":"14","author":"Huang","year":"2008","journal-title":"World Journal of Gastroenterology"},{"key":"10.1016\/j.molmet.2020.101122_bib95","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.jhep.2004.08.020","article-title":"Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease","volume":"41","author":"Angulo","year":"2004","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.molmet.2020.101122_bib96","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.metabol.2015.11.006","article-title":"Adipokines in nonalcoholic fatty liver disease","volume":"65","author":"Polyzos","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.molmet.2020.101122_bib97","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/pr.2014.202","article-title":"Adipocyte-derived exosomal miRNAs: a novel mechanism for obesity-related disease","volume":"77","author":"Ferrante","year":"2015","journal-title":"Pediatric Research"},{"key":"10.1016\/j.molmet.2020.101122_bib98","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1007\/s00018-018-2860-6","article-title":"Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease","volume":"75","author":"Ipsen","year":"2018","journal-title":"Cellular and Molecular Life Sciences"},{"key":"10.1016\/j.molmet.2020.101122_bib99","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.metabol.2010.10.003","article-title":"Lipid in the livers of adolescents with nonalcoholic steatohepatitis: combined effects of pathways on steatosis","volume":"60","author":"Zhu","year":"2011","journal-title":"Metabolism"},{"key":"10.1016\/j.molmet.2020.101122_bib100","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1136\/gut.2010.222844","article-title":"Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C","volume":"60","author":"Miquilena-Colina","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.molmet.2020.101122_bib101","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00535-019-01633-2","article-title":"Hepatic FATP5 expression is associated with histological progression and loss of hepatic fat in NAFLD patients","volume":"55","author":"Enooku","year":"2020","journal-title":"Journal of Gastroenterology"},{"key":"10.1016\/j.molmet.2020.101122_bib102","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1053\/j.gastro.2013.11.049","article-title":"Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease","volume":"146","author":"Lambert","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmet.2020.101122_bib103","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.molmet.2020.101122_bib104","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S1262-3636(07)70061-7","article-title":"Contribution of hepatic de novo lipogenesis and reesterification of plasma non esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease","volume":"29","author":"Diraison","year":"2003","journal-title":"Diabetes & Metabolism"},{"key":"10.1016\/j.molmet.2020.101122_bib105","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1194\/jlr.M200461-JLR200","article-title":"Differences in the regulation of adipose tissue and liver lipogenesis by carbohydrates in humans","volume":"44","author":"Diraison","year":"2003","journal-title":"The Journal of Lipid Research"},{"key":"10.1016\/j.molmet.2020.101122_bib106","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1172\/JCI115206","article-title":"Measurement of de novo hepatic lipogenesis in humans using stable isotopes","volume":"87","author":"Hellerstein","year":"1991","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.molmet.2020.101122_bib107","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/ajcn\/73.2.253","article-title":"Postprandial de novo lipogenesis and metabolic changes induced by a high-carbohydrate, low-fat meal in lean and overweight men","volume":"73","author":"Marques-Lopes","year":"2001","journal-title":"American Journal of Clinical Nutrition"},{"key":"10.1016\/j.molmet.2020.101122_bib108","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1172\/JCI134165","article-title":"Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease","volume":"130","author":"Smith","year":"2020","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.molmet.2020.101122_bib109","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.jhep.2008.12.016","article-title":"Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH","volume":"50","author":"Caballero","year":"2009","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.molmet.2020.101122_bib110","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cmet.2007.12.009","article-title":"Selective versus total insulin resistance: a pathogenic paradox","volume":"7","author":"Brown","year":"2008","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.molmet.2020.101122_bib111","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1172\/JCI41636","article-title":"The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans","volume":"122","author":"Benhamed","year":"2012","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.molmet.2020.101122_bib112","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/j.1872-034X.2008.00382.x","article-title":"Liver X receptor in cooperation with SREBP-1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease","volume":"38","author":"Higuchi","year":"2008","journal-title":"Hepatology Research"},{"key":"10.1016\/j.molmet.2020.101122_bib113","doi-asserted-by":"crossref","first-page":"16381","DOI":"10.1073\/pnas.1113359108","article-title":"Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease","volume":"108","author":"Kumashiro","year":"2011","journal-title":"Proceedings of the National Academy of Sciences of the U S A"},{"key":"10.1016\/j.molmet.2020.101122_bib114","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1053\/j.gastro.2012.03.003","article-title":"Intrahepatic diacylglycerol content is associated with hepatic insulin resistance in obese subjects","volume":"142","author":"Magkos","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmet.2020.101122_bib115","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jhep.2016.01.002","article-title":"Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease","volume":"64","author":"Luukkonen","year":"2016","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.molmet.2020.101122_bib116","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1172\/JCI86013","article-title":"Insulin receptor Thr1160 phosphorylation mediates lipid-induced hepatic insulin resistance","volume":"126","author":"Petersen","year":"2016","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.molmet.2020.101122_bib117","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.2337\/db16-1147","article-title":"Mechanisms of insulin resistance in primary and secondary nonalcoholic fatty liver","volume":"66","author":"Jelenik","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2020.101122_bib118","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.2337\/dc17-1318","article-title":"Specific hepatic sphingolipids relate to insulin resistance, oxidative stress, and inflammation in nonalcoholic steatohepatitis","volume":"41","author":"Apostolopoulou","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.molmet.2020.101122_bib119","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/hep.31095","article-title":"Ceramides: a cause of insulin resistance in nonalcoholic fatty liver disease in both murine models and humans","volume":"71","author":"Yki-Jarvinen","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.molmet.2020.101122_bib120","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1053\/jhep.2001.28055","article-title":"High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis","volume":"34","author":"Paradis","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.molmet.2020.101122_bib121","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.cmet.2015.04.004","article-title":"Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis","volume":"21","author":"Koliaki","year":"2015","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.molmet.2020.101122_bib122","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1001\/jama.282.17.1659","article-title":"Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study","volume":"282","author":"Cortez-Pinto","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.molmet.2020.101122_bib123","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1111\/liv.13451","article-title":"Ultra-high-field magnetic resonance spectroscopy in non-alcoholic fatty liver disease: novel mechanistic and diagnostic insights of energy metabolism in non-alcoholic steatohepatitis and advanced fibrosis","volume":"37","author":"Traussnigg","year":"2017","journal-title":"Liver International"},{"key":"10.1016\/j.molmet.2020.101122_bib124","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1002\/hep.23093","article-title":"Abnormal hepatic energy homeostasis in type 2 diabetes","volume":"50","author":"Szendroedi","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.molmet.2020.101122_bib125","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.3945\/ajcn.115.107599","article-title":"Time course of postprandial hepatic phosphorus metabolites in lean, obese, and type 2 diabetes patients","volume":"102","author":"Fritsch","year":"2015","journal-title":"American Journal of Clinical Nutrition"},{"key":"10.1016\/j.molmet.2020.101122_bib126","doi-asserted-by":"crossref","first-page":"448","DOI":"10.2337\/dc10-1076","article-title":"Liver ATP synthesis is lower and relates to insulin sensitivity in patients with type 2 diabetes","volume":"34","author":"Schmid","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.molmet.2020.101122_bib127","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/toxsci\/kft230","article-title":"The adaptive endoplasmic reticulum stress response to lipotoxicity in progressive human nonalcoholic fatty liver disease","volume":"137","author":"Lake","year":"2014","journal-title":"Toxicological Sciences"},{"key":"10.1016\/j.molmet.2020.101122_bib128","doi-asserted-by":"crossref","first-page":"20704","DOI":"10.3390\/ijms141020704","article-title":"Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH)","volume":"14","author":"Takaki","year":"2013","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.molmet.2020.101122_bib129","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1161\/CIRCRESAHA.117.311401","article-title":"Reactive oxygen species in metabolic and inflammatory signaling","volume":"122","author":"Forrester","year":"2018","journal-title":"Circulation Research"},{"key":"10.1016\/j.molmet.2020.101122_bib130","first-page":"32","article-title":"Effects of L-carnitine against oxidative stress in human hepatocytes: involvement of peroxisome proliferator-activated receptor alpha","volume":"19","author":"Li","year":"2012","journal-title":"Journal of Biomedical Sciences"},{"key":"10.1016\/j.molmet.2020.101122_bib131","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nature13478","article-title":"The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes","volume":"510","author":"Perry","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.molmet.2020.101122_bib132","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1053\/j.gastro.2007.11.038","article-title":"Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease","volume":"134","author":"Fabbrini","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmet.2020.101122_bib133","doi-asserted-by":"crossref","first-page":"15430","DOI":"10.1073\/pnas.0904944106","article-title":"Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity","volume":"106","author":"Fabbrini","year":"2009","journal-title":"Proceedings of the National Academy of Sciences of the U S A"},{"key":"10.1016\/j.molmet.2020.101122_bib134","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00125-005-0125-z","article-title":"Overproduction of large VLDL particles is driven by increased liver fat content in man","volume":"49","author":"Adiels","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.molmet.2020.101122_bib135","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s00535-013-0758-5","article-title":"Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease","volume":"48","author":"Kawano","year":"2013","journal-title":"Journal of Gastroenterology"},{"key":"10.1016\/j.molmet.2020.101122_bib136","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1053\/jhep.2002.32527","article-title":"Apolipoprotein synthesis in nonalcoholic steatohepatitis","volume":"35","author":"Charlton","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.molmet.2020.101122_bib137","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3892\/etm.2011.328","article-title":"Effects of insulin resistance and hepatic lipid accumulation on hepatic mRNA expression levels of apoB, MTP and L-FABP in non-alcoholic fatty liver disease","volume":"2","author":"Higuchi","year":"2011","journal-title":"Experimental and Therapeutic Medicine"},{"key":"10.1016\/j.molmet.2020.101122_bib138","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/hep.23094","article-title":"Dysfunctional very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis","volume":"50","author":"Fujita","year":"2009","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/j.molmet.2020.101122_bib139","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jhep.2010.04.033","article-title":"Down-regulation of SREBP-1c is associated with the development of burned-out NASH","volume":"53","author":"Nagaya","year":"2010","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.molmet.2020.101122_bib140","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3390\/cells9020461","article-title":"Cellular interplay as a consequence of inflammatory signals leading to liver fibrosis development","volume":"9","author":"Ignat","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.molmet.2020.101122_bib141","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1053\/j.gastro.2019.11.311","article-title":"Mechanisms of fibrosis development in nonalcoholic steatohepatitis","volume":"158","author":"Schwabe","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmet.2020.101122_bib142","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41575-018-0082-x","article-title":"The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"16","author":"Kazankov","year":"2019","journal-title":"Nature Reviews Gastroenterology & Hepatology"},{"key":"10.1016\/j.molmet.2020.101122_bib143","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1016\/j.ajpath.2015.03.024","article-title":"NADPH oxidase-derived peroxynitrite drives inflammation in mice and human nonalcoholic steatohepatitis via TLR4-lipid raft recruitment","volume":"185","author":"Das","year":"2015","journal-title":"American Journal of Pathology"},{"key":"10.1016\/j.molmet.2020.101122_bib144","doi-asserted-by":"crossref","first-page":"G949","DOI":"10.1152\/ajpgi.00215.2003","article-title":"Human hepatic stellate cells express CCR5 and RANTES to induce proliferation and migration","volume":"285","author":"Schwabe","year":"2003","journal-title":"American Journal of Physiology - Gastrointestinal and Liver Physiology"},{"key":"10.1016\/j.molmet.2020.101122_bib145","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3389\/fphys.2015.00329","article-title":"Cytoglobin as a marker of hepatic stellate cell-derived myofibroblasts","volume":"6","author":"Kawada","year":"2015","journal-title":"Frontiers in Physiology"},{"key":"10.1016\/j.molmet.2020.101122_bib146","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/cr.2009.73","article-title":"Lipid accumulation in hepatocytes induces fibrogenic activation of hepatic stellate cells","volume":"19","author":"Wobser","year":"2009","journal-title":"Cell Research"},{"key":"10.1016\/j.molmet.2020.101122_bib147","doi-asserted-by":"crossref","first-page":"4737","DOI":"10.3390\/ijms21134737","article-title":"Elucidating potential profibrotic mechanisms of emerging biomarkers for early prognosis of hepatic fibrosis","volume":"21","author":"Zehra","year":"2020","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.molmet.2020.101122_bib148","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1136\/gut.2004.042127","article-title":"Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis","volume":"54","author":"Xu","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.molmet.2020.101122_bib149","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jhep.2017.11.012","article-title":"Determinants of fibrosis progression and regression in NASH","volume":"68","author":"Schuppan","year":"2018","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.molmet.2020.101122_bib150","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41586-018-0522-3","article-title":"Mechanosensing by beta1 integrin induces angiocrine signals for liver growth and survival","volume":"562","author":"Lorenz","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.molmet.2020.101122_bib151","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.248","article-title":"ER stress induces NLRP3 inflammasome activation and hepatocyte death","volume":"6","author":"Lebeaupin","year":"2015","journal-title":"Cell Death & Disease"},{"key":"10.1016\/j.molmet.2020.101122_bib152","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.actbio.2015.06.028","article-title":"Designing a fibrotic microenvironment to investigate changes in human liver sinusoidal endothelial cell function","volume":"24","author":"Ford","year":"2015","journal-title":"Acta Biomaterialia"},{"key":"10.1016\/j.molmet.2020.101122_bib153","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0207923","article-title":"Validity of ultrasonography to assess hepatic steatosis compared to magnetic resonance spectroscopy as a criterion method in older adults","volume":"13","author":"De Lucia Rolfe","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.molmet.2020.101122_bib154","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0094059","article-title":"Comparison of liver fat indices for the diagnosis of hepatic steatosis and insulin resistance","volume":"9","author":"Kahl","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.molmet.2020.101122_bib155","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/0284185115580488","article-title":"A comparison of liver fat content as determined by magnetic resonance imaging-proton density fat fraction and MRS versus liver histology in non-alcoholic fatty liver disease","volume":"57","author":"Idilman","year":"2016","journal-title":"Acta Radiologica"},{"key":"10.1016\/j.molmet.2020.101122_bib156","doi-asserted-by":"crossref","DOI":"10.3390\/nu10020157","article-title":"Liver fat scores moderately reflect interventional changes in liver fat content by a low-fat diet but not by a low-carb diet","volume":"10","author":"Kabisch","year":"2018","journal-title":"Nutrients"},{"key":"10.1016\/j.molmet.2020.101122_bib157","doi-asserted-by":"crossref","first-page":"290","DOI":"10.2337\/dc19-1071","article-title":"Performance of plasma biomarkers and diagnostic panels for nonalcoholic steatohepatitis and advanced fibrosis in patients with type 2 diabetes","volume":"43","author":"Bril","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.molmet.2020.101122_bib158","doi-asserted-by":"crossref","first-page":"9127","DOI":"10.3390\/nu7115454","article-title":"Nutritional modulation of non-alcoholic fatty liver disease and insulin resistance","volume":"7","author":"Yki-Jarvinen","year":"2015","journal-title":"Nutrients"},{"key":"10.1016\/j.molmet.2020.101122_bib159","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jhep.2017.05.016","article-title":"Treatment of NAFLD with diet, physical activity and exercise","volume":"67","author":"Romero-Gomez","year":"2017","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.molmet.2020.101122_bib160","doi-asserted-by":"crossref","first-page":"603","DOI":"10.2337\/diabetes.54.3.603","article-title":"Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes","volume":"54","author":"Petersen","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2020.101122_bib161","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/hep.24242","article-title":"Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects","volume":"53","author":"Haufe","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.molmet.2020.101122_bib162","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1093\/ajcn\/nqy358","article-title":"Yogurt improves insulin resistance and liver fat in obese women with nonalcoholic fatty liver disease and metabolic syndrome: a randomized controlled trial","volume":"109","author":"Chen","year":"2019","journal-title":"American Journal of Clinical Nutrition"},{"key":"10.1016\/j.molmet.2020.101122_bib163","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1053\/j.gastro.2016.10.007","article-title":"Isocaloric diets high in animal or plant protein reduce liver fat and inflammation in individuals with type 2 diabetes","volume":"152","author":"Markova","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmet.2020.101122_bib164","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1002\/hep.30076","article-title":"Ad libitum mediterranean and low-fat diets both significantly reduce hepatic steatosis: a randomized controlled trial","volume":"68","author":"Properzi","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.molmet.2020.101122_bib165","doi-asserted-by":"crossref","DOI":"10.3390\/nu9080870","article-title":"Effect of mediterranean diet and antioxidant formulation in non-alcoholic fatty liver disease: a randomized study","volume":"9","author":"Abenavoli","year":"2017","journal-title":"Nutrients"},{"key":"10.1016\/j.molmet.2020.101122_bib166","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jhep.2013.02.012","article-title":"The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease","volume":"59","author":"Ryan","year":"2013","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.molmet.2020.101122_bib167","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/j.gastro.2014.04.046","article-title":"No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial","volume":"147","author":"Sanyal","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmet.2020.101122_bib168","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.clnu.2015.05.001","article-title":"Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled trial","volume":"35","author":"Nogueira","year":"2016","journal-title":"Clinical Nutrition"},{"key":"10.1016\/j.molmet.2020.101122_bib169","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/j.clnu.2018.09.022","article-title":"Critical appraisal for low-carbohydrate diet in nonalcoholic fatty liver disease: review and meta-analyses","volume":"38","author":"Ahn","year":"2019","journal-title":"Clinical Nutrition"},{"key":"10.1016\/j.molmet.2020.101122_bib170","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.metabol.2016.12.006","article-title":"Effects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease: a meta-analysis","volume":"68","author":"Katsagoni","year":"2017","journal-title":"Metabolism"},{"key":"10.1016\/j.molmet.2020.101122_bib171","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00125-014-3457-8","article-title":"Low-energy diets differing in fibre, red meat and coffee intake equally improve insulin sensitivity in type 2 diabetes: a randomised feasibility trial","volume":"58","author":"Nowotny","year":"2015","journal-title":"Diabetologia"},{"key":"10.1016\/j.molmet.2020.101122_bib172","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1007\/s00125-019-4956-4","article-title":"A carbohydrate-reduced high-protein diet improves HbA1c and liver fat content in weight stable participants with type 2 diabetes: a randomised controlled trial","volume":"62","author":"Skytte","year":"2019","journal-title":"Diabetologia"},{"key":"10.1016\/j.molmet.2020.101122_bib173","doi-asserted-by":"crossref","DOI":"10.3390\/nu11030677","article-title":"Impact of nutritional changes on nonalcoholic fatty liver disease","volume":"11","author":"Perdomo","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.molmet.2020.101122_bib174","doi-asserted-by":"crossref","first-page":"j1957","DOI":"10.1136\/bmj.j1957","article-title":"Mortality from different causes associated with meat, heme iron, nitrates, and nitrites in the NIH-AARP Diet and Health Study: population based cohort study","volume":"357","author":"Etemadi","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.molmet.2020.101122_bib175","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.tem.2019.07.013","article-title":"Are lifestyle therapies effective for NAFLD treatment?","volume":"30","author":"El-Agroudy","year":"2019","journal-title":"Trends in Endocrinology and Metabolism"},{"key":"10.1016\/j.molmet.2020.101122_bib176","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1136\/gut.2011.242073","article-title":"Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss","volume":"60","author":"Hallsworth","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.molmet.2020.101122_bib177","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11892-017-0867-2","article-title":"The Janus head of oxidative stress in metabolic diseases and during physical exercise","volume":"17","author":"Pesta","year":"2017","journal-title":"Current Diabetes Reports"},{"key":"10.1016\/j.molmet.2020.101122_bib178","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.cgh.2018.10.017","article-title":"Complete resolution of nonalcoholic fatty liver disease after bariatric surgery: a systematic review and meta-analysis","volume":"17","author":"Lee","year":"2019","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1016\/j.molmet.2020.101122_bib179","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1038\/s41467-019-12081-0","article-title":"Dynamic changes of muscle insulin sensitivity after metabolic surgery","volume":"10","author":"Gancheva","year":"2019","journal-title":"Nature Communications"},{"key":"10.1016\/j.molmet.2020.101122_bib180","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.cmet.2013.07.004","article-title":"DNA methylation analysis in nonalcoholic fatty liver disease suggests distinct disease-specific and remodeling signatures after bariatric surgery","volume":"18","author":"Ahrens","year":"2013","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.molmet.2020.101122_bib181","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s11695-010-0228-6","article-title":"NAFLD and insulin resistance do not increase the risk of postoperative complications among patients undergoing bariatric surgery-a prospective analysis","volume":"21","author":"Ribeireiro","year":"2011","journal-title":"Obesity Surgery"},{"key":"10.1016\/j.molmet.2020.101122_bib182","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3390\/cells9010037","article-title":"Anti-NASH drug development hitches a lift on PPAR agonism","volume":"9","author":"Boeckmans","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.molmet.2020.101122_bib183","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.molmet.2020.101122_bib184","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2008.06.047","article-title":"Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis","volume":"135","author":"Aithal","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmet.2020.101122_bib185","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.molmet.2020.101122_bib186","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-Term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.molmet.2020.101122_bib187","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3346\/jkms.2017.32.1.60","article-title":"Lobeglitazone, a novel thiazolidinedione, improves non-alcoholic fatty liver disease in type 2 diabetes: its efficacy and predictive factors related to responsiveness","volume":"32","author":"Lee","year":"2017","journal-title":"Journal of Korean Medical Science"},{"key":"10.1016\/j.molmet.2020.101122_bib188","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1136\/gutjnl-2019-319104","article-title":"Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges","volume":"69","author":"Dufour","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.molmet.2020.101122_bib189","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmet.2020.101122_bib190","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1080\/13543784.2016.1216970","article-title":"The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetes","volume":"25","author":"Pafili","year":"2016","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1016\/j.molmet.2020.101122_bib191","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.molmet.2020.101122_bib192","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1080\/17512433.2019.1635453","article-title":"Sodium-glucose cotransporter-2 inhibitors in type 2 diabetes: a magic potion to reduce heart failure?","volume":"12","author":"Pafili","year":"2019","journal-title":"Expert Review of Clinical Pharmacology"},{"key":"10.1016\/j.molmet.2020.101122_bib193","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2337\/dc18-1569","article-title":"The SGLT2 inhibitor dapagliflozin reduces liver fat but does not affect tissue insulin sensitivity: a randomized, double-blind, placebo-controlled study with 8-week treatment in type 2 diabetes patients","volume":"42","author":"Latva-Rasku","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.molmet.2020.101122_bib194","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/dom.13520","article-title":"Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"21","author":"Shimizu","year":"2019","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"10.1016\/j.molmet.2020.101122_bib195","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00125-018-4675-2","article-title":"Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study","volume":"61","author":"Eriksson","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.molmet.2020.101122_bib196","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1210\/jc.2011-2260","article-title":"Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin","volume":"97","author":"Bolinder","year":"2012","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"key":"10.1016\/j.molmet.2020.101122_bib197","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/dom.13584","article-title":"Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes","volume":"21","author":"Cusi","year":"2019","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"10.1016\/j.molmet.2020.101122_bib198","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s10620-019-05573-y","article-title":"Fat and fibrosis: does empagliflozin impair the progression of nonalcoholic steatohepatitis in patients with type 2 diabetes mellitus?","volume":"65","author":"Khan","year":"2020","journal-title":"Digestive Diseases and Sciences"},{"key":"10.1016\/j.molmet.2020.101122_bib199","series-title":"EASL dILC2020","article-title":"Resolution of non-alcoholic steatohepatitis and hepatic fibrosis by sodium glucose transporter-2 inhibitor, ipragliflozin; a multicenter randomized controlled trial","author":"Takahashi","year":"2020"},{"key":"10.1016\/j.molmet.2020.101122_bib200","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1007\/s12325-020-01498-5","article-title":"Effect of empagliflozin on liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease without diabetes: a randomized, double-blind, placebo-controlled trial","volume":"37","author":"Taheri","year":"2020","journal-title":"Advances in Therapy"},{"key":"10.1016\/j.molmet.2020.101122_bib201","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1038\/ajg.2010.363","article-title":"Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series","volume":"105","author":"Kenny","year":"2010","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.molmet.2020.101122_bib202","first-page":"407","article-title":"Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes: the lira-NAFLD study","volume":"102","author":"Petit","year":"2017","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"key":"10.1016\/j.molmet.2020.101122_bib203","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jhep.2015.08.038","article-title":"Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis","volume":"64","author":"Armstrong","year":"2016","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.molmet.2020.101122_bib204","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00125-019-05021-6","article-title":"Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation","volume":"63","author":"Bizino","year":"2020","journal-title":"Diabetologia"},{"key":"10.1016\/j.molmet.2020.101122_bib205","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/dom.12680","article-title":"Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy","volume":"18","author":"Dutour","year":"2016","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"10.1016\/j.molmet.2020.101122_bib206","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.2337\/dc19-1892","article-title":"Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes","volume":"43","author":"Hartman","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.molmet.2020.101122_bib207","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.2337\/db14-0052","article-title":"Pleiotropic mechanisms for the glucose-lowering action of DPP-4 inhibitors","volume":"63","author":"Omar","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2020.101122_bib208","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3389\/fendo.2019.00389","article-title":"Clinical use of DPP-4 inhibitors","volume":"10","author":"Gallwitz","year":"2019","journal-title":"Frontiers in Endocrinology (Lausanne)"},{"key":"10.1016\/j.molmet.2020.101122_bib209","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jhep.2016.04.021","article-title":"Sitagliptin vs. placebo for non-alcoholic fatty liver disease: a randomized controlled trial","volume":"65","author":"Cui","year":"2016","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.molmet.2020.101122_bib210","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3748\/wjg.v23.i1.141","article-title":"Sitagliptin in patients with non-alcoholic steatohepatitis: a randomized, placebo-controlled trial","volume":"23","author":"Joy","year":"2017","journal-title":"World Journal of Gastroenterology"},{"key":"10.1016\/j.molmet.2020.101122_bib211","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1007\/s00125-016-4100-7","article-title":"Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial","volume":"59","author":"Smits","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.molmet.2020.101122_bib212","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/MEG.0000000000000780","article-title":"Short article: a randomized-controlled study of sitagliptin for treating diabetes mellitus complicated by nonalcoholic fatty liver disease","volume":"29","author":"Deng","year":"2017","journal-title":"European Journal of Gastroenterology and Hepatology"},{"key":"10.1016\/j.molmet.2020.101122_bib213","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2147\/HMER.S158053","article-title":"Effect of sitagliptin on hepatic histological activity and fibrosis of nonalcoholic steatohepatitis patients: a 1-year randomized control trial","volume":"10","author":"Alam","year":"2018","journal-title":"Hepatic Medicine"},{"key":"10.1016\/j.molmet.2020.101122_bib214","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1002\/hep.30320","article-title":"Liraglutide, sitagliptin, and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease","volume":"69","author":"Yan","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.molmet.2020.101122_bib215","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1210\/jc.2014-3794","article-title":"Effect of vildagliptin on hepatic steatosis","volume":"100","author":"Macauley","year":"2015","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"key":"10.1016\/j.molmet.2020.101122_bib216","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1517\/14656560903176453","article-title":"Metformin: diamonds are forever","volume":"10","author":"Papanas","year":"2009","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1016\/j.molmet.2020.101122_bib217","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1080\/00365520902845268","article-title":"Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial","volume":"44","author":"Haukeland","year":"2009","journal-title":"Scandinavian Journal of Gastroenterology"},{"key":"10.1016\/j.molmet.2020.101122_bib218","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3892\/br.2012.18","article-title":"Metformin in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"1","author":"Li","year":"2013","journal-title":"Biomedical Reports"},{"key":"10.1016\/j.molmet.2020.101122_bib219","doi-asserted-by":"crossref","first-page":"154","DOI":"10.2337\/diacare.28.1.154","article-title":"Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis","volume":"28","author":"van de Laar","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.molmet.2020.101122_bib220","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.jhep.2009.05.017","article-title":"Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease","volume":"51","author":"Nozaki","year":"2009","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.molmet.2020.101122_bib221","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.bbrc.2004.01.116","article-title":"Acarbose attenuates experimental non-alcoholic steatohepatitis","volume":"315","author":"Lieber","year":"2004","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.molmet.2020.101122_bib222","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jhep.2010.02.004","article-title":"Combination of acarbose and ezetimibe prevents non-alcoholic fatty liver disease: a break of intestinal insulin resistance?","volume":"52","author":"Rudovich","year":"2010","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.molmet.2020.101122_bib223","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1111\/hepr.13223","article-title":"Miglitol attenuates non-alcoholic steatohepatitis in diabetic patients","volume":"48","author":"Komatsu","year":"2018","journal-title":"Hepatology Research"},{"key":"10.1016\/j.molmet.2020.101122_bib224","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.molmet.2018.01.005","article-title":"Reversal of metabolic disorders by pharmacological activation of bile acid receptors TGR5 and FXR","volume":"9","author":"Jadhav","year":"2018","journal-title":"Molecular Metabolism"},{"key":"10.1016\/j.molmet.2020.101122_bib225","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.molmet.2020.101122_bib226","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.molmet.2020.101122_bib227","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/hep.29477","article-title":"A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis","volume":"67","author":"Friedman","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.molmet.2020.101122_bib228","doi-asserted-by":"crossref","DOI":"10.1002\/hep.31108","article-title":"Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis: final analysis of the phase 2b CENTAUR study","author":"Ratziu","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.molmet.2020.101122_bib229","article-title":"One-year results of the global phase 2b randomized placebo-controlled arrest trial of aramchol, a stearoyl CoA desaturase inhibitor, in patients with NASH","volume":"68","author":"Ratziu","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.molmet.2020.101122_bib230","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1053\/j.gastro.2018.07.027","article-title":"GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease","volume":"155","author":"Loomba","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmet.2020.101122_bib231","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/cpdd.782","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of a liver-targeting acetyl-CoA carboxylase inhibitor (PF-05221304): a three-Part Randomized phase 1 study","volume":"9","author":"Bergman","year":"2020","journal-title":"Clinical Pharmacology in Drug Development"},{"key":"10.1016\/j.molmet.2020.101122_bib232","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1016\/S0618-8278(19)30122-7","article-title":"PS-110-Ketohexokinase inhibitor PF-06835919 administered for 6 weeks reduces whole liver fat as measured by magnetic resonance imaging-proton density fat fraction in subjects with non-alcoholic fatty liver disease","volume":"70","author":"Calle","year":"2019","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.molmet.2020.101122_bib233","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/hep.31296","article-title":"Thyroid hormone signaling and the liver","volume":"72","author":"Ritter","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.molmet.2020.101122_bib234","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jcmgh.2019.04.007","article-title":"Metabolic targets in nonalcoholic fatty liver disease","volume":"8","author":"Esler","year":"2019","journal-title":"Cellular and Molecular Gastroenterology and Hepatology"},{"key":"10.1016\/j.molmet.2020.101122_bib235","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.molmet.2020.101122_bib236","doi-asserted-by":"crossref","first-page":"E89","DOI":"10.1152\/ajpendo.00573.2012","article-title":"Thyroid hormone receptor-beta agonists prevent hepatic steatosis in fat-fed rats but impair insulin sensitivity via discrete pathways","volume":"305","author":"Vatner","year":"2013","journal-title":"American Journal of Physiology. Endocrinology and Metabolism"},{"key":"10.1016\/j.molmet.2020.101122_bib237","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.jhep.2019.10.023","article-title":"Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase IIb study","volume":"72","author":"Harrison","year":"2020","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.molmet.2020.101122_bib238","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","article-title":"Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial","volume":"392","author":"Sanyal","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.molmet.2020.101122_bib239","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/hep.30590","article-title":"NGM282 improves liver fibrosis and histology in 12 Weeks in patients with nonalcoholic steatohepatitis","volume":"71","author":"Harrison","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.molmet.2020.101122_bib240","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","article-title":"Non-alcoholic fatty liver disease - a global public health perspective","volume":"70","author":"Younossi","year":"2019","journal-title":"Journal of Hepatology"}],"container-title":["Molecular Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212877820301964?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212877820301964?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:27:45Z","timestamp":1761956865000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212877820301964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":240,"alternative-id":["S2212877820301964"],"URL":"https:\/\/doi.org\/10.1016\/j.molmet.2020.101122","relation":{},"ISSN":["2212-8778"],"issn-type":[{"value":"2212-8778","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans","name":"articletitle","label":"Article Title"},{"value":"Molecular Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmet.2020.101122","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"101122"}}